Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TACE With Dicycloplatin（TP21） in Patients With Unresectable Hepatocellular Carcinoma: an Open, Parallel-controlled,Multicenter Randomized Phase III Trial

NCT05472896 is registered in ClinicalTrials.gov with Gao-jun Teng as lead sponsor.

NCT NCT05472896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05472896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TACE With Dicycloplatin（TP21） in Patients With Unresectable Hepatocellular Carcinoma: an Open, Parallel-controlled,Multicenter Randomized Phase III Trial
Lead sponsor
Gao-jun Teng
Phase
Phase 3
Overall status
Unknown status
Start date
June 9, 2022
Completion date
June 30, 2024
Enrollment
332 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma